Scientists explored clinical factors in 332 advanced NSCLC who received EGFR TKI and molecular characteristics through 65 whole exome sequencing of various EGFR TKI responses including; de novo, intermediate response and long-term response.
[Scientific Reports]
7992332
{7992332:AAAAAAAA}
apa
50
1
171687
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/